Receptor-activating autoantibodies and disease: Preeclampsia and beyond

Expert Review of Clinical Immunology

Volumn 7, Issue 5, 2011, Pages 659-674

  Xia, Yang ^a   Kellems, Rodney E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

1 adrenergic receptor; 1 adrenergic receptor; agonistic autoantibodies; allograft rejection; angiotensin receptor; dilated cardiomyopathy; endothelin receptor; Graves' disease; hypertension; preeclampsia; systemic sclerosis; thyroid stimulating hormone receptor; thyrotropin receptor

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 6; LONG ACTING THYROID STIMULATOR; LOSARTAN; RITUXIMAB; THYROID HORMONE; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BINDING ASSAY; BLOOD PRESSURE MEASUREMENT; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS CIRCULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; FOLLOW UP; GRAFT SURVIVAL; GRAVES DISEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; IMMUNOADSORPTION; INTRACELLULAR SIGNALING; INTRAUTERINE GROWTH RETARDATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALIGNANT HYPERTENSION; MATERNAL HYPERTENSION; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PREECLAMPSIA; PROTEIN PHOSPHORYLATION; PROTEINURIA; PULMONARY HYPERTENSION; REVIEW; SURFACE PLASMON RESONANCE; SYSTEMIC SCLEROSIS; X RAY DIFFRACTION;

ANIMALS; AUTOANTIBODIES; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; SCLERODERMA, SYSTEMIC;

EID: 80052622829     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.56     Document Type: Review

References (105)

1. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J. Clin. Invest. 115(8), 1972-1983 (2005). (Pubitemid 41134132)
2. Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmun. Rev. 9(2), 113-116 (2009).
3. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84(3), 223-243 (1997). (Pubitemid 27398022)
4. Adams DD, Fastier FN, Howie JB, Kennedy TH, Kilpatrick JA, Stewart RD. Stimulation of the human thyroid by infusions of plasma containing LATS protector. J. Clin. Endocrinol. Metab. 39(5), 826-832 (1974).
5. Costagliola S, Rodien P, Many MC, Ludgate M, Vassart G. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J. Immunol. 160(3), 1458-1465 (1998). (Pubitemid 28093448)
6. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur. J. Endocrinol./Eur. Federat. Endocrine Soc. 160(1), 1-8 (2009).
7. Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves' disease. Lancet 2(7878), 427-431 (1974).
8. Ajjan RA, Weetman AP. Techniques to quantify TSH receptor antibodies. Nat. Clin. Pract. Endocrinol. Metab. 4(8), 461-468 (2008).
9. Sanders J, Evans M, Premawardhana LD et al. Human monoclonal thyroid stimulating autoantibody. Lancet 362(9378), 126-128 (2003). (Pubitemid 36831025)
10. Smith BR, Bolton J, Young S et al. A new assay for thyrotropin receptor autoantibodies. Thyroid 14(10), 830-835 (2004). (Pubitemid 39489008)
11. Nakatake N, Sanders J, Richards T et al. Estimation of serum TSH receptor autoantibody concentration and affinity. Thyroid 16(11), 1077-1084 (2006). (Pubitemid 44864482)
12. El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin. Immunol. 130(3), 252-258 (2009).
13. Sanders J, Jeffreys J, Depraetere H et al. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. Thyroid 14(8), 560-570 (2004). (Pubitemid 39097076)
14. Smith BR, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid 17(10), 923-938 (2007). (Pubitemid 350071602)
15. Sanders J, Chirgadze DY, Sanders P et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 17(5), 395-410 (2007). (Pubitemid 46878842)
16. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J. Clin. Invest. 105(6), 803-811 (2000). (Pubitemid 30164119)
17. Nagayama Y, Kita-Furuyama M, Ando T et al. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol. 168(6), 2789-2794 (2002). (Pubitemid 34211657)
18. Borda E, Pascual J, Cossio P, De La Vega M, Arana R, Sterin-Borda L. A circulating IgG in Chagas' disease which binds to β-adrenoceptors of myocardium and modulates their activity. Clin. Exp. Immunol. 57(3), 679-686 (1984). (Pubitemid 14057727)
19. Jahns R, Boivin V, Lohse MJ. b(1)- Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc. Med. 16(1), 20-24 (2006). (Pubitemid 43012037)
20. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against β-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ. Res. 64(1), 97-103 (1989). (Pubitemid 19028507)
21. Magnusson Y, Marullo S, Hoyer S et al. Mapping of a functional autoimmune epitope on the b 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J. Clin. Invest. 86(5), 1658-1663 (1990). (Pubitemid 20372617)
22. Wallukat G, Morwinski M, Kowal K, Forster A, Boewer V, Wollenberger A. Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitization. Eur. Heart. J. 12(Suppl. D), 178-181 (1991).
23. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β 1-adrenoceptor with positive chronotropic effect. Circulation 89(6), 2760-2767 (1994). (Pubitemid 24173697)
24. Magnusson Y, Hjalmarson A, Hoebeke J. β 1-adrenoceptor autoimmunity in cardiomyopathy. Int. J. Cardiol. 54(2), 137-141 (1996).
25. Mobini R, Fu M, Wallukat G, Magnusson Y, Hjalmarson A, Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human β 1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma 19(2), 135-142 (2000). (Pubitemid 30387232)
26. Nikolaev VO, Boivin V, Stork S et al. A novel fluorescence method for the rapid detection of functional β 1-adrenergic receptor autoantibodies in heart failure. J. Am. Coll. Cardiol. 50(5), 423-431 (2007). (Pubitemid 47088126)
27. Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the β- and muscarinic receptors in cardiomyopathy. Herz 25(3), 261-266 (2000). (Pubitemid 30422174)
28. Munoz-Saravia SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas' heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail. Rev. DOI: 10.1007/s10741-010-9211-5 (2010) (Epub ahead of print).
29. Wallukat G, Munoz Saravia SG, Haberland A et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients. J. Am. Coll. Cardiol. 55(5), 463-468 (2010).
30. Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ. Pathological autoantibodies in cardiomyopathy. Autoimmunity 41(6), 454-461 (2008).
31. Ferrari I, Levin MJ, Wallukat G et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human β 1-adrenergic receptor. J. Exp. Med. 182(1), 59-65 (1995).
32. Wallukat G, Wollenberger A. Effects of the serum γ globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic β adrenoceptor function in cultured neonatal rat heart myocytes. Biomedica Biochimica Acta 46(8-9), S634-S639 (1987).
33. Jahns R, Boivin V, Hein L et al. Direct evidence for a β 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest. 113(10), 1419-1429 (2004). (Pubitemid 39071697)
34. Jahns R, Boivin V, Lohse MJ. β 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int. J. Cardiol. 112(1), 7-14 (2006). (Pubitemid 44247194)
35. Christ T, Wettwer E, Dobrev D et al. Autoantibodies against the β 1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J. Mol. Cell. Cardiol. 33(8), 1515-1525 (2001). (Pubitemid 32681669)
36. Deubner N, Berliner D, Schlipp A et al. Cardiac β 1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur. J. Heart Fail. 12(7), 753-762 (2010).
37. Fu ML, Herlitz H, Wallukat G et al. Functional autoimmune epitope on a 1-adrenergic receptors in patients with malignant hypertension. Lancet 344(8938), 1660-1663 (1994). (Pubitemid 24371095)
38. Luther HP, Homuth V, Wallukat G. α 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 29(2), 678-682 (1997). (Pubitemid 27074736)
39. Wenzel K, Haase H, Wallukat G et al. Potential relevance of α (1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS ONE 3(11), e3742 (2008).
40. Yan L, Xu Y, Yao H et al. The effects of autoantibodies against the second extracellular loop of α (1)-adrenoceptor on vasoconstriction. Basic Res. Cardiol. 104(5), 581-589 (2009).
41. Wenzel K, Wallukat G, Qadri F et al. α 1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats. PLoS ONE 5(2), e9409 (2010).
42. Karczewski P, Haase H, Hempel P, Bimmler M. Agonistic antibody to the α 1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol. Cell. Biochem. 333(1-2), 233-242 (2009).
43. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Ann. Rev. Pathol. 5, 173-192 (2010).
44. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 357, 53-56 (2001). (Pubitemid 32056505)
45. Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J. Immunol. 179(6), 3391-3395 (2007).
46. Lamarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 51(4), 982-988 (2008). (Pubitemid 351398991)
47. Xia Y, Kellems RE. Is preeclampsia an autoimmune disease? Clin. Immunol. 133(1), 1-12 (2009).
48. Wenzel K, Rajakumar A, Haase H et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 58(1), 77-84 (2011).
49. Herse F, Verlohren S, Wenzel K et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 53(2), 393-398 (2009).
50. 1 receptor. J. Clin. Invest. 103(7), 945-952 (1999). (Pubitemid 29169601)
51. 1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107(12), 1632-1639 (2003). (Pubitemid 36401560)
52. Dechend R, Homuth V, Wallukat G et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 101(20), 2382-2387 (2000). (Pubitemid 30329128)
53. Bobst SM, Day MC, Gilstrap LC 3rd, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am. J. Hypertens. 18(3), 330-336 (2005). (Pubitemid 40409912)
54. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J. Soc. Gynecol. Invest. 10(2), 82-93 (2003). (Pubitemid 36184763)
55. Zhou CC, Ahmad S, Mi T et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 51(4), 1010-1019 (2008). (Pubitemid 351398948)
56. Zhou CC, Irani RA, Zhang Y et al. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-α induction contributes to increased soluble endoglin production in preeclampsia. Circulation 121(3), 436-444 (2010).
57. 1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J. Hypertens. 26(8), 1629-1635 (2008).
58. Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med. 14(8), 855-862 (2008).
59. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 55(2), 386-393 (2010).
60. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reproduct. 69(1), 1-7 (2003). (Pubitemid 36806800)
61. Barker DJ. In utero programming of chronic disease. Clin. Sci. (Lond.) 95(2), 115-128 (1998). (Pubitemid 28401260)
62. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am. J. Clin. Nutrit. 71(Suppl. 5), S1344-S1352 (2000).
63. Baum M, Ortiz L, Quan A. Fetal origins of cardiovascular disease. Curr. Opin. Pediat. 15(2), 166-170 (2003). (Pubitemid 36337827)
64. Irani RA, Zhang Y, Blackwell SC et al. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J. Exp. Med. 206(12), 2809-2822 (2009).
65. Gadonski G, Lamarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension 48(4), 711-716 (2006). (Pubitemid 44843876)
66. Gilbert JS, Ryan MJ, Lamarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 294(2), H541-H550 (2008). (Pubitemid 351253261)
67. Parrish MR, Murphy SR, Rutland S et al. The effect of immune factors, tumor necrosis factor-α, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am. J. Hypertens. 23(8), 911-916 (2010).
68. Li Z, Zhang Y, Ying Ma J et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50(4), 686-692 (2007). (Pubitemid 47442732)
69. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor a in pregnant rats. Hypertension 52(6), 1168-1172 (2008).
70. 1-AA) in pregnant rats: role of endothelin-1. Hypertension 54(4), 905-909 (2009).
71. Lamarca B, Wallace K, Herse F et al. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 57(4), 865-871 (2011).
72. + T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension 57(5), 949-955 (2011).
73. 1 receptor in a transgenic rat model of preeclampsia. Hypertension 45(4), 742-746 (2005). (Pubitemid 40418375)
74. 1 receptor in immunized rats. Acta Pharmacol. Sin. 31(10), 1381-1388 (2010).
75. Irani RA, Zhang Y, Zhou CC et al. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension 55(5), 1246-1253 (2010).
76. Zhou CC, Irani RA, Dai Y et al. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J. Immunol. 186(10), 6024-6034 (2011).
77. Zhou CC, Irani RA, Zhang Y et al. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-α induction contributes to increased soluble endoglin production in preeclampsia. Circulation 121(3), 436-444 (2010).
78. 1-AA: Role of reactive oxygen species in pregnancy-induced hypertension. Am. J. Hypertens. 24(7), 835-840 (2011).
79. Parrish MR, Ryan MJ, Glover P et al. Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction. Gender Med. 8(3), 184-188.
80. 1-AA) in preeclampsia. Curr. Opin. Pharmacol. 11(2), 175-179 (2011).
81. Dragun D, Brasen JH, Schonemann C et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant. Proc. 35(6), 2104-2105 (2003). (Pubitemid 37194332)
82. Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352(6), 558-569 (2005). (Pubitemid 40204669)
83. Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol. Dial. Transplant. 22(7), 1819-1822 (2007). (Pubitemid 47244747)
84. 1) in patients with hypertension. J. Hypertens. 18(7), 945-953 (2000). (Pubitemid 30459497)
85. 1 receptor autoantibodies. Heart 97(6), 479-484 (2011).
86. 1 receptor from hypertension. Chinese Med. J. 121(1), 43-48 (2008).
87. 1-receptor and α1-adrenergic receptor in patients with hypertension. Hypertens. Res. 25(4), 641-646 (2002).
88. Dragun D. The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediat. Nephrol. (Berlin, Germany) 22(7), 911-914 (2007). (Pubitemid 46881907)
89. Reinsmoen NL, Lai CH, Heidecke H et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 90(12), 1473-1477 (2010).
90. Riemekasten G, Philippe A, Nather M et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann. Rheum. Dis. 70(3), 530-536 (2010).
91. Walllukat GDM, Muller J, Bartel S, Schulze W, Hetzer R. Agonistic autoantibodies against the endothelin 1 ETA- and a 1-adrenergic receptor in the sera of patients with idiopathic pulmonary arterial hypertension. Circulation 116(II), 503 (2007).
92. Dandel MWG, Englert A, Lehmkul HB, Hetzer R. Potential pathogenetic involvement of agonistic autoantibodies against a-1 adrenergic and endothelin-1 receptors in pulmonary arterial hypertension. Circulation 118, S1072 (2008).
93. Dandel MWG, Englert A, Lehmkul HB, Hetzer R. Agonistic autoantibodies against a-1 adrenergic and endothelin-1 receptors in sera of patients with pulmonary arterial hypertension: potential involvement in the pathogenesis of the disease. J. Heart Lung Transplant. 28(2), S249 (2009).
94. Dragun D, Philippe A, Catar R, Hegner B. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thrombo. Haemost. 101(4), 643-648 (2009).
95. Walther T, Wallukat G, Jank A et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 46(6), 1275-1279 (2005). (Pubitemid 43189723)
96. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, Mclachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J. Clin. Invest. 111(12), 1897-1904 (2003). (Pubitemid 38057734)
97. Mizutori Y, Chen CR, Latrofa F, Mclachlan SM, Rapoport B. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease. J. Clin. Endocrinol. Metab. 94(3), 927-935 (2009).
98. Gigler A, Dorsch S, Hemauer A et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 73(3), 1974-1979 (1999). (Pubitemid 29098099)
99. Stepan H, Wallukat G, Schultheiss HP, Faber R, Walther T. Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor? J. Reprod. Immunol. 73(2), 130-134 (2007). (Pubitemid 46402938)
100. Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell. Signalling 16(2), 175-186 (2004). (Pubitemid 37431167)
101. Breitwieser GE. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Cir. Res. 94(1), 17-27 (2004). (Pubitemid 38064094)
102. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Reports 5(1), 30-34 (2004). (Pubitemid 38228524)
103. 1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407(6800), 94-98 (2000).
104. Abdalla S, Lother H, El Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med. 7(9), 1003-1009 (2001). (Pubitemid 32937379)
105. Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol. Rev. 82(2), 473-502 (2002). (Pubitemid 34654459)